Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction – 10/11/2024 at 5:45 p.m.

[ad_1]

• 27 patients recruited in the phase 2b LIBERATE study evaluating glenzocimab in the treatment of ST-segment elevation myocardial infarction (STEMI)

• Preparation of a new phase 2 study, GLORIA, evaluating glenzocimab in angioplasty for STEMI

Paris, France, October 11, 2024 – 5:45 p.m. CEST – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical-stage biopharmaceutical company specializing in the development of innovative drugs for the treatment of cardiovascular emergencies and in particular acute thrombotic diseases, made today an update on its clinical developments, evaluating glenzocimab in the treatment of myocardial infarction.

[ad_2]

Source link -86